Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data

S. Sevcikova, H. Paszekova, L. Besse, L. Sedlarikova, V. Kubaczkova, M. Almasi, L. Pour, R. Hajek

. 2015 ; 159 (2) : 288-293. [pub] 20150416

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17006064

Grantová podpora
NT14575 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Multiple myeloma (MM) is characterized by malignant proliferation of plasma cells (PC) which accumulate in the bone marrow (BM). The advent of new drugs has changed the course of the disease from incurable to treatable, but most patients eventually relapse. One group of MM patients (10-15%) is considered high-risk because they relapse within 24 months. Recently, extramedullary relapse of MM (EM) has been observed more frequently. Due to its aggressivity and shorter survival, EM is also considered high-risk. AIMS: The goal of this study was to determine if the so-called high-risk genes published by the University of Arkansas group (UAMS) are even more deregulated in EM patients than in high-risk MM patients and if these patients may be considered high-risk. METHODS: Nine samples of bone marrow plasma cells from MM patients as well as 9 tumors and 9 bone marrow plasma cells from EM patients were used. Quantitative real-time PCR was used for evaluation of expression of 15 genes connected to the high-risk signature of MM patients. RESULTS: Comparison of high-risk plasma cells vs extramedullary plasma cells revealed 4 significantly deregulated genes (CKS1B, CTBS, NADK, YWHAZ); moreover, comparison of extramedullary plasma cells vs extramedullary tumors revealed significant differences in 9 out of 15 genes. Of these, 6 showed significant changes as described by the UAMS group (ASPM, SLC19A1, NADK, TBRG4, TMPO and LARS2). CONCLUSIONS: Our data suggest that increasing genetic abnormalities as described by the gene expression data are associated with increased risk for EM relapse.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17006064
003      
CZ-PrNML
005      
20200219094156.0
007      
ta
008      
170210s2015 xr f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2015.014 $2 doi
035    __
$a (PubMed)25877407
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ševčíková, Sabina, $d 1972- $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno $7 mub2015859787
245    10
$a Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data / $c S. Sevcikova, H. Paszekova, L. Besse, L. Sedlarikova, V. Kubaczkova, M. Almasi, L. Pour, R. Hajek
520    9_
$a BACKGROUND: Multiple myeloma (MM) is characterized by malignant proliferation of plasma cells (PC) which accumulate in the bone marrow (BM). The advent of new drugs has changed the course of the disease from incurable to treatable, but most patients eventually relapse. One group of MM patients (10-15%) is considered high-risk because they relapse within 24 months. Recently, extramedullary relapse of MM (EM) has been observed more frequently. Due to its aggressivity and shorter survival, EM is also considered high-risk. AIMS: The goal of this study was to determine if the so-called high-risk genes published by the University of Arkansas group (UAMS) are even more deregulated in EM patients than in high-risk MM patients and if these patients may be considered high-risk. METHODS: Nine samples of bone marrow plasma cells from MM patients as well as 9 tumors and 9 bone marrow plasma cells from EM patients were used. Quantitative real-time PCR was used for evaluation of expression of 15 genes connected to the high-risk signature of MM patients. RESULTS: Comparison of high-risk plasma cells vs extramedullary plasma cells revealed 4 significantly deregulated genes (CKS1B, CTBS, NADK, YWHAZ); moreover, comparison of extramedullary plasma cells vs extramedullary tumors revealed significant differences in 9 out of 15 genes. Of these, 6 showed significant changes as described by the UAMS group (ASPM, SLC19A1, NADK, TBRG4, TMPO and LARS2). CONCLUSIONS: Our data suggest that increasing genetic abnormalities as described by the gene expression data are associated with increased risk for EM relapse.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a buněčné klony $7 D002999
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a exprese genu $7 D015870
650    _2
$a geny nádorové $x genetika $7 D052138
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x genetika $7 D009101
650    _2
$a plazmatické buňky $x fyziologie $7 D010950
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a recidiva $7 D012008
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Paszekova, Helena $u Institute of Pathological Physiology, 1st Faculty of Medicine, Charles University in Prague
700    1_
$a Bešše, Lenka, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno $d 1985- $7 mub2014851432
700    1_
$a Sedlaříková, Lenka $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno $7 xx0214571
700    1_
$a Kubaczková, Veronika $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0214572
700    1_
$a Almáši, Martina $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno $7 xx0122075
700    1_
$a Pour, Luděk $u Department of Internal Medicine - Hematooncology, University Hospital Brno $7 xx0102556
700    1_
$a Hájek, Roman, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno; Department of Clinical Studies, Faculty of Medicine, University of Ostrava $d 1964- $7 nlk20000083645
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 159, č. 2 (2015), s. 288-293
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170210 $b ABA008
991    __
$a 20200219094558 $b ABA008
999    __
$a ok $b bmc $g 1192589 $s 966711
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 159 $c 2 $d 288-293 $e 20150416 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
GRA    __
$a NT14575 $p MZ0
LZP    __
$b NLK118 $a Pubmed-20170210

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace